Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
YUTREPIA
product4 mentionslast seen Nov 10, 2026
Inhaled dry-powder formulation of treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Relationships 14
- YUTREPIAapplies topulmonary arterial hypertension treatment99% confidence3 sources
- Liquidia CorporationdevelopsYUTREPIA99% confidence3 sources
- YUTREPIAdepends onPRINT technology99% confidence2 sources
- YUTREPIAapplies topulmonary hypertension associated with interstitial lung disease treatment99% confidence2 sources
- U.S. Food and Drug AdministrationapprovesYUTREPIA97% confidence1 source
- U.S. Food and Drug AdministrationapprovesYUTREPIA97% confidence1 source
- Liquidia CorporationcommercializesYUTREPIA96% confidence1 source
- Liquidia Technologies, Inc.commercializesYUTREPIA95% confidence1 source
- YUTREPIAcomposed oftreprostinil95% confidence1 source
- U.S. Food and Drug AdministrationapprovesYUTREPIA95% confidence1 source
- YUTREPIAcomposed ofPRINT technology93% confidence1 source
- YUTREPIAapplies topulmonary hypertension treatment90% confidence1 source
- YUTREPIAapplies topulmonary hypertension associated with chronic obstructive pulmonary disease treatment82% confidence1 source
- YUTREPIAapplies tosystemic sclerosis-associated Raynaud's phenomenon treatment82% confidence1 source
Relationship
YUTREPIAdepends onPRINT technology
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 10, 2026Liquidia Corp 8-K: Item 2.02: Results of Operations and Financial Condition; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
YUTREPIA was designed using Liquidia's PRINT® technology
- filingSEC EDGARSep 30, 2026Liquidia Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
YUTREPIA was designed using Liquidia's PRINT® technology